The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days
Biosimilar medicines are available in therapy areas which represent 65% of the biologics market by value
In Europe, biosimilar medicines have captured 7% more of the biologics market over a 5-year period
Growing number of biologic therapies offers future opportunities for biosimilar development
Physicians recognised potential of Value Added Medicines
Medicines Shortages: Causes and Recommendations
How can your healthcare system support a wider access to Value Added Medicines?
Infographic: Value Added Medicines Provide a Wide Range of Different and Important Benefits to Patients, Healthcare Professionals and Healthcare Systems
